Contract

Financial Analyst 2

Temporary

Posted on 10/3/2025

Deadline 8/11/26
Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center

1,001-5,000 employees

Nonprofit cancer treatment, research, and trials

Compensation Overview

$80.5k - $120.7k/yr

No H1B Sponsorship

Seattle, WA, USA

In Person

Category
Finance & Banking (1)
Required Skills
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in accounting or finance.
  • Minimum of two years of experience in accounting or finance, preferable in a research or not-for-profit environment.
  • Working knowledge of financial information and related operational statistics.
  • Ability to develop and perform complex calculations in MicroSoft Excel and Access.
  • Strong analytical skills with attention to detail.
  • Well-developed verbal and written communication skills, including an ability to understand complex problems, to collaborate and explore alternative solutions.
  • Ability to work independently on multiple projects and communicate status of projects to key decision makers on a proactive basis.
Responsibilities
  • Project manage all aspects of the study startup process for clinical trials to include industry-sponsored, investigator initiated and grant funded trials.
  • Identify research costs and develop and negotiate comprehensive budgets for industry-sponsored, investigator initiated and grant funded trials.
  • Prepare, submit, and manage study startup documentation across multiple platforms, including the OnCore CTMS, REDCap system, and email.
  • Facilitate pre-implementation meetings with PIs and study teams to review pre-submission requirements.
  • Prepare, submit and manage internal financial processes and coordinate with clinic implementation staff.
  • Collaborate with cancer consortium parallel offices and clinic partners to ensure all institutional pre-activation requirements are met.
  • Partner with study startup team, clinical trial staff, central regulatory operations team, and consortium study teams to communicate start-up process, milestones, and timeline goals.
  • Prepare, submit, and manage financial document updates across multiple platforms (e.g., OnCore CTMS, REDcap, and email) that result from protocol amendments and/or other changes as needed.
  • Create multi-year and annual budgets. Monitor financial performance relative to budget and explain variances and trends.
  • Monitor and track monthly labor and non-labor spending for allocation of appropriate costs to Sponsored projects.
  • Provide Budget-to-actual financial reporting, expense approvals, and invoice processing while assuring charges are appropriate, allowable, allocable, and paid promptly.
  • Assist with ongoing financial analysis, forecasting, and ad hoc financial models.
  • Review internal billing compliance documents and OnCore study calendars to ensure financial infrastructure is sound and in alignment with protocol requirements and study sponsor funding terms.
  • Work professionally and proactively with central offices, clinic partners, faculty members, and research collaborators in support of the overall research plan.
  • Assist with other departmental fiscal objectives as needed and provide recommendations for changes in processes or practices that standardize, automate and optimize efficiencies in routine tasks.
Desired Qualifications
  • Experience with fiscal management of Phase I-III clinical trials.
  • Experience developing complex, multi-phase clinical trial budgets; negotiating study budgets and revisions and knowledge of medical terminology.
  • Clinical research related certification.
  • Demonstrated familiarity with process improvement principles.
  • Demonstrated familiarity with project management tools and techniques.
  • Experience performing clinical trial management/administration and/or sponsor invoicing activities utilizing OnCore or another CTMS system.
  • Experience performing or reviewing clinical trial management/administration activities utilizing EPIC or another patient billing and registration system.
Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center

View

Fred Hutchinson Cancer Center is a nonprofit cancer treatment and research institute serving the Pacific Northwest and beyond. It provides a full range of cancer care, including treatments that may not be available elsewhere, and offers patients the chance to participate in clinical trials. The center accomplishes its work through a combination of patient care, research grants, and fundraising, and collaborates with UW Medicine and other regional providers to extend its reach. Internationally, it operates facilities in Uganda and South Africa to advance research and collaboration. The organization’s revenue comes from patient services, grants, and fundraising events. Its central goal is to eliminate cancer and related diseases by improving treatments and ultimately finding a cure.

Company Size

1,001-5,000

Company Stage

Grant

Total Funding

$300K

Headquarters

Seattle, Washington

Founded

1975

Simplify Jobs

Simplify's Take

What believers are saying

  • Ai2, Google Cloud add $20M to Cancer AI Alliance's $40M funding.
  • Global sites in Uganda, South Africa enable diverse AI training data.
  • NCI-designated center since 1973 drives research grants, fundraising.

What critics are saying

  • AWS, Microsoft, NVIDIA cut commitments, halting 2025 AI results.
  • Dana-Farber, MSK erode Fred Hutch's precision oncology referrals.
  • NIH grants lapse, Obliteride donors drop in recession by 2027.

What makes Fred Hutchinson Cancer Center unique

  • Fred Hutch leads Cancer AI Alliance coordinating Dana-Farber, MSK, Johns Hopkins.
  • Offers 750+ active clinical trials, most in Pacific Northwest.
  • Pioneers precision oncology via Stuart and Molly Sloan Institute.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

Paid Parental Leave

Sabbatical Leave

Tuition Reimbursement

Company News

GeekWire
Apr 17th, 2025
Tech Moves: Smartsheet Names Chief Product Officer; Meta Vet Joins Tech Alliance; And More

Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Arora. (Smartsheet Photo)— Pratima Arora has been named chief product officer at Smartsheet, a new senior executive role at the Bellevue, Wash.-based enterprise software giant.A longtime product and technology leader, Arora will be responsible for Smartsheet’s product management, product marketing, user experience, pricing and packaging, and digital and product partnerships.She previously held senior leadership roles at Atlassian and Salesforce, and was most recently the chief product and technology officer at Chainalysis.“After a fantastic 4-month break to recharge, spend quality time with family, and dive deep into the world of GenAI, I’m energized and ready for what’s next,” Arora said on LinkedIn. “There’s no better place than Smartsheet to begin this new chapter. With a strong foundation, a passionate customer base, and a unique opportunity to reimagine collaborative work through AI, the road ahead is full of possibility.”Smartsheet also announced that Nick Dunn, an eight-year veteran of the company, is now general counsel, responsible for leading the company’s legal, privacy, and risk functions, including corporate governance initiatives.Launched in 2005, Smartsheet makes cloud-based enterprise work management technologies for managing and tracking projects, collaborating, storing data, and automating and assigning tasks, among other capabilities. It serves 85% of the Fortune 500 as customers

PR Newswire
Apr 4th, 2025
Google Cloud And Ai2 Commit $20M To Advance Ai-Powered Research For The Cancer Ai Alliance

Google Cloud to provide advanced and secure technology, while Ai2 to lead AI training and development for AI cancer modelsSEATTLE and SUNNYVALE, Calif., April 4, 2025 /PRNewswire/ -- Today, Google Cloud and Ai2 announced they have partnered with the Cancer AI Alliance (CAIA), a pioneering consortium uniting leading cancer research institutions and technology companies to harness artificial intelligence (AI) in the fight against cancer. Google Cloud and Ai2 are each giving $10 million to the initiative and providing access to technology solutions that will help speed scientific discovery. Google Cloud will power planet-scale AI infrastructure and data analytics tools, while Ai2 will provide critical expertise in training large-scale models focusing on cancer research

GeekWire
Apr 4th, 2025
Ai2 And Google Cloud Join Cancer Ai Alliance With A Total Of $20M In Commitments

Inside the Allen Institute for AI in Seattle. (GeekWire File Photo / Todd Bishop)The Allen Institute for AI (Ai2) is joining a high-profile national effort to accelerate cancer research using artificial intelligence, committing $10 million in researcher time and technical expertise to the Cancer AI Alliance, a consortium led by the Fred Hutch Cancer Center.Google Cloud is also committing $10 million in resources to the effort, planning to provide computing infrastructure and tools to help process large volumes of cancer data. They say the goal is to create a novel AI infrastructure that supports the training and deployment of AI models across institutions while maintaining data security and privacy standards for patients.The Cancer AI Alliance was announced in October 2024 as a joint effort among four major cancer centers: Fred Hutch, Dana-Farber, Memorial Sloan Kettering, and Johns Hopkins. Backed by more than $40 million in initial support from AWS, Microsoft, NVIDIA, Deloitte, and Slalom, the project aims to use artificial intelligence to analyze large volumes of cancer data across institutions. Seattle-based Fred Hutch is serving as the lead coordinating center.Ai2 CEO Ali Farhadi in his Seattle office. (GeekWire File Photo / Todd Bishop)In a previous interview with GeekWire, Ai2 CEO Ali Farhadi said the Cancer AI Alliance represents the kind of real-world challenge that needs customized, domain-specific AI models. The Seattle-based AI institute focuses on open-source artificial intelligence technologies.Farhadi said Ai2’s role in the Cancer AI Alliance reflects Ai2’s goal to apply cutting-edge research where it can have the most tangible impact on the world.“Any step in the right direction in that space is going to be a risk worth taking, and that’s the kind of impact that we’re after,” Farhadi said, explaining Ai2’s ambitions for 2025 on the GeekWire Podcast. “If you’re actually trying to solve a real problem, there is no turnkey solution.”The Cancer AI Alliance has said it expects initial research results by the end of 2025

GeekWire
Mar 18th, 2025
Geekwire Awards: Health Innovation Of The Year Field Is Dominated By Finalists Battling Cancer

The 2025 GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with groundbreaking new technologies. The contenders range from a newly formed startup to a leading U.S. cancer institute and companies in between. Joining the cohort is a business with technology to help healthcare providers better manage appointments and access to providers.This awards category recognizes pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for improving peoples’ lives and enhancing the healthcare system.The finalists are Archon Biosciences, DexCare, Fred Hutch Cancer Center, Talus Bioscience and Umoja Biopharma.Last year’s winner was CalmWave, a Seattle health-tech startup that created a system for making sense of the alarms triggered by the devices that monitor hospital ICU patients.Continue reading for details on each of this year’s finalists, and vote here or below.Archon BiosciencesArchon Biosciences emerged from stealth last October with $20 million in funding. The Seattle biotech company is running with technology developed in the lab of University of Washington biochemist and Nobel Prize winner David Baker.Archon’s proprietary protein structures, known as Antibody Cages or AbCs, combine two biomedical tools — naturally occurring antibodies and custom-designed proteins — to create a single new protein structure. These protein structures, or AbCs, are optimized with the aid of generative AI to travel in the body in controllable ways and engage with target cells in a more specific manner.“What we like to say is, it’s not whether you’re given a drug, it’s how you’re given it,” said CEO and co-founder James Lazarovits

GeekWire
Mar 12th, 2025
Tech Moves: Longtime Google Leader Umesh Shankar Joins Microsoft As New Corporate Vp

Umesh Shankar. (LinkedIn Photo). After nearly 19 years at Google, Umesh Shankar has joined Microsoft AI as a corporate vice president of engineering.Shankar, based in New York City, has focused his career on privacy and security. His last role at Google was chief technologist and distinguished engineer for Google Cloud Security. Shankar will lead a new privacy and security engineering effort focused on Microsoft’s Copilot AI assistant, according to Microsoft AI CEO Mustafa Suleyman.“I believe that investing in a secure technical foundation will actually allow us to innovate with AI faster than we could in a world where giving AI more data and tools comes with unknown or unbounded risk,” he said on LinkedIn. “That’s why I’ll be focusing on building systems and platforms that have strong protections and user control built in.”Shankar is the latest Google leader to join Microsoft AI in recent months

INACTIVE